AMGN's consistent top-line growth, an interesting pipeline and rising estimates are good enough reasons to stay invested in the stock for now.
Zenas BioPharma (ZBIO) stock rises as Wedbush issues a bullish recommendation based on the company's lead asset obexelimab. Read more here.
Investing.com -- Fitch Ratings has revised its outlook for biopharmaceutical company Amgen Inc (NASDAQ: AMGN ). to positive ...
Horizon Therapeutics Plc presented positive new MRI data from the phase 3 clinical trial of UPLIZNA (inebilizumab) at the 9th Congress of the European Academy of Neurology (EAN) in Budapest ...
Last November, results from the MITIGATE trial made headlines at ACR Convergence 2024 with positive phase 3 trial data for inebilizumab, an IgG1 monoclonal antibody targeting CD19, in patients with ...
Amgen’s innovative R&D pipeline is promising, with recent approvals for IMDELLTRA™ and BLINCYTO®, and positive clinical data for TEZSPIRE® and UPLIZNA®. The pipeline features potentially ...
Clinical Trials Arena on MSN5d
Immunovant will not seek approval for MG therapy, despite hitting endpointsThe company plans to use results from its Phase III myasthenia gravis study to support its pipeline candidate IMVT-1402 over ...
It has some rivals in its push to the IgG4-RD market, notably Amgen which reported positive topline results from a phase 3 trial of its CD19-directed antibody Uplizna (inebilizumab), acquired as ...
Wedbush initiated coverage on Zenas BioPharma, Inc. (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company focused ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback